Scholarlink

Background <p>Non-interventional studies indicate an association between Torque Teno Virus (TTV) load in peripheral blood and immunosuppression related outcomes in kidney transplant recipients. This makes it a promising biomarker for guiding immunosuppression after kidney transplantation. The primary objective of the current trial is to demonstrate the safety, tolerability and preliminary efficacy of TTV-guided immunosuppression.</p> Methods <p>For this purpose, a randomised, controlled, interventional, two-arm, non-inferiority, patient- and assessor-blinded, international multicentre investigator-driven phase II trial was designed. A total of 260 stable, low-immunological-risk adult recipients of a kidney graft with Tacrolimus-based immunosuppression and TTV infection after month 3 post-transplant are recruited in 13 academic centres in six European countries. Subjects are randomised in a 1:1 ratio stratified by centre (allocation concealment) to receive Tacrolimus either guided by TTV load or according to the local centre standard for 9&#xa0;months. The primary composite endpoint includes the occurrence of infections, biopsy-proven allograft rejection, graft loss or death. Secondary outcomes include month 12 protocol biopsies, development of de novo donor-specific antibodies, health-related quality of life and drug adherence.</p> Discussion <p>Detailed descriptions of the study design, planned statistical analysis and reporting of the results for the TTVguideIT trial are provided. This statistical analysis plan was submitted to the journal before the end of the trial and prior to data lock.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Statistical analysis plan for TTVguideIT—a multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and Torque Teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Felix Herkner,
  • Frederik Haupenthal,
  • Sebastian Kapps,
  • Konstantin Doberer,
  • Harald Herkner,
  • Franz König,
  • Gregor Bond

摘要

Background

Non-interventional studies indicate an association between Torque Teno Virus (TTV) load in peripheral blood and immunosuppression related outcomes in kidney transplant recipients. This makes it a promising biomarker for guiding immunosuppression after kidney transplantation. The primary objective of the current trial is to demonstrate the safety, tolerability and preliminary efficacy of TTV-guided immunosuppression.

Methods

For this purpose, a randomised, controlled, interventional, two-arm, non-inferiority, patient- and assessor-blinded, international multicentre investigator-driven phase II trial was designed. A total of 260 stable, low-immunological-risk adult recipients of a kidney graft with Tacrolimus-based immunosuppression and TTV infection after month 3 post-transplant are recruited in 13 academic centres in six European countries. Subjects are randomised in a 1:1 ratio stratified by centre (allocation concealment) to receive Tacrolimus either guided by TTV load or according to the local centre standard for 9 months. The primary composite endpoint includes the occurrence of infections, biopsy-proven allograft rejection, graft loss or death. Secondary outcomes include month 12 protocol biopsies, development of de novo donor-specific antibodies, health-related quality of life and drug adherence.

Discussion

Detailed descriptions of the study design, planned statistical analysis and reporting of the results for the TTVguideIT trial are provided. This statistical analysis plan was submitted to the journal before the end of the trial and prior to data lock.